Literature DB >> 16981232

Differential capacity of anti-RAP and anti-megalin antibodies to produce progressive passive Heymann nephritis - implications for the pathogenesis of idiopathic human membranous glomerulonephritis.

S P Makker1, A Tramontano.   

Abstract

Passive Heymann nephritis (PHN) induced with heterologous antisera has been described according to various criteria, which may or may not include induction of chronic disease and proteinuria. Characteristics of the glomerular immune deposits determined by the antigenic specificities of the antisera presumably account for differences in disease outcome. In this study, the clinical and immunohistological features in the model produced with monospecific antisera were compared against megalin or receptor associated protein (RAP), two proteins that have been implicated as target antigens in PHN. Rats injected with either anti-megalin or anti-RAP antiserum developed typical glomerular immune deposits of PHN when examined after 7 days. Although the deposits stained for complement, none of the animals had abnormal proteinuria in this time frame. Over a longer time course (7-16 weeks), immune deposits persisted and proteinuria increased to pathological levels in all animals injected with anti-megalin serum. By contrast, immune deposits had cleared from the kidneys of rats injected with anti-RAP antiserum when examined at 7-8 weeks post-injection and the proteinuria levels observed up to 13 weeks remained in the normal range. Additional doses of anti-RAP antiserum given 4 and 17 days after the first injection did not prolong the duration of glomerular immune deposits. These results demonstrate a clear divergence in pathogenic potential of antisera generated against the two renal antigens, which suggest differences in the immune deposits linked to a soluble antigen that is non-covalently bound to the podocyte membrane versus those linked to an integral membrane antigen. These observations could provide clues to the nature of the unknown glomerular autoantigen of idiopathic membranous glomerulonephritis in humans. Copyright 2006 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981232     DOI: 10.1002/path.2058

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  4 in total

Review 1.  Idiopathic membranous nephropathy: an autoimmune disease.

Authors:  Sudesh P Makker; Alfonso Tramontano
Journal:  Semin Nephrol       Date:  2011-07       Impact factor: 5.299

2.  Experimental Models of Membranous Nephropathy.

Authors:  J Ashley Jefferson; Jeffrey W Pippin; Stuart J Shankland
Journal:  Drug Discov Today Dis Models       Date:  2010

3.  Artemisinin analogue SM934 ameliorates the proteinuria and renal fibrosis in rat experimental membranous nephropathy.

Authors:  Tian-tian Li; Xiao-hui Zhang; Jing-feng Jing; Xin Li; Xiao-qian Yang; Feng-hua Zhu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2015-01-26       Impact factor: 6.150

Review 4.  Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men.

Authors:  P Ronco; H Debiec
Journal:  Semin Immunopathol       Date:  2007-09-26       Impact factor: 9.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.